Wuxi Junuo, An Independent Innovative Biotechnology Company, Announced That In 2022 The American Society Of Clinical Oncology (Asco) Annual Meeting Presents The Latest Clinical Research Data Of Benoda In Poster Presentations And Online Presentations.Benoda (Ruiji Orenza Injection) Is A Cd19-Targeting Drug Independently Developed By Wuxi Ju Nuo On The Basis Of The Car-T Cell Technology Platform Of Ju Nuo Medical (A Bristol-Myers Squibb Company) Of Autologous Car-T Cell Immunotherapy Products. As Wuxi Junuo'S First Product, Benoda Was Approved By The China National Medical Products Administration In September 2021 For The Treatment Of Relapsed Or Refractory Large B Cells In Adult Patients After Second-Line Or Above Systemic Therapy Lymphoma (R/R Lbcl), Became The First Car-T Product Approved As A Class 1 Biological Product In China. Benoda Is Currently The Only Car- T Cell Immunotherapy Product In China That Has Received Three Awards At The Same Time, Including The "Major New Drug Creation" Project, The Priority Review Qualification For New Drug Marketing Applications, And The Breakthrough Therapy Drug Designation.Wuxi Junuo Is An Independent, Innovative Biotechnology Company Focused On The Development, Production And Commercialization Of Cellular Immunotherapy Products.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!